Submissions from 2024
Safety of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) in Participants With Recurrent Clostridioides difficile Infection and Comorbidities: Findings From an Integrated Analysis of Phase 3 Trials, Matthew Sims, Charles S. Berenson, Robert Stevens, DIanne Nguyen, and John R. Pullman
Where Are the Antibodies? A Case of Prolonged COVID19 Infection in an Immunocompromised Patient Status Post Rituximab Therapy, Fiona Tissavirasingham, Shivani Singh, and Enrique Calvo-Ayala
Submissions from 2023
True Pressure of a Disease: Disseminated Cryptococcal Infection in a Renal Transplant Patient, Unnati Bhatia, Ioannis Karageorgiou, and Carmen Demarco
Eustachian Valve Endocarditis Caused by Staphylococcus pettenkoferi and Complicated by DRESS Syndrome: A Rare Case Report, Karan Chhabra, Sam Alsabti, Paige Spagna, Nishaki Mehta, Carl Lauter, and Carmen DeMarco
O-serotype Distribution of Escherichia Coli Causing Invasive Disease in Tertiary Care Hospital Patients, Jeroen Geurtsen, Joachim Doua, Luis Martinez-Martinez, Patricia I. de Palacios, Jeff Powis, Matthew Sims, Peter Hermans, Oliver Barraud, Philippe Lanotte, Joshua T. Thaden, Oscar Go, Bart Spiessens, Darren Abbanat, Florian Wagenlehner, Tetsuya Matsumoto, Marc Bonten, Michal Sarnecki, and Jan Poolman
The Impact of Age on Microbiome Diversity and Engraftment of Fecal Microbiota Spores, Live (FMS) in Patients With Recurrent Clostridioides difficile Infection, Anne J. Gonzales-Luna, Kevin D. Litcofsky, Timothy J. Straub, Dina Hot, Brooke Hassan, Matthew Sims, Jennifer R. Wortman, Matthew R. Hen, and Barbara McGovern
Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides Difficile Infection (rCDI), Anne J. Gonzales-Luna, Kevin Litcofsky, Tim Straub, Dina Hot, Barbara McGovern, Brooke Hasson, Matthew Sims, Christopher Ford, and Matthew Henn
An Integrated Safety and Efficacy Analysis of Phase 3 ECOSPOR III and ECOSPOR IV Studies of Fecal Microbiota Spores, live-brpk (Vost TM; VOS; Formerly SER-109) in Recurrent Clostridioides difficile Infection, Anne J. Gonzales-Luna, Matthew D. Sims, David A. Lombardi, Lisa von Moltke, and Sissi V. Pham
Social Determinants of Health in Extended Spectrum Beta-Lactamase Carriage in the Urine - The Influence of Race, Ethnicity and Sex in the Outpatient Setting, Jenna Herkness and Matthew Sims
Not Worth Your Weight in Silver: Stain Negative PCR Positive Pneumocystis Jirovecii Pneumonia, Ioannis Karageorgiou, Unnati Bhatia, and Carmen Demarco
Understanding the Barriers to Sexual Health in Middle Eastern Immigrant Women, Noora Kazanji, Hana Masri, and Laura Power
Low Birthweight and Retention in HIV Care Among Postpartum Women Living With HIV in Ghana, Noora Kazanji, Kwame Sakyi, and Bianca Edler
A Rare Case of Disseminated Histoplasmosis in Immunocompetent Adult With Alcoholic Liver Cirrhosis, Marko Kozyk, Kateryna Strubchevska, and John Szela
Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection, Matthew Sims, Michael Silverman, Thomas Louie, Elaine Wang, Colleen Kraft, Mayur Ramesh, Tatiana Bogdanovich, Kelly Brady, David Lombardi, and Asli Memisoglu
Submissions from 2022
Incidence of hospitalizations in ECOSPOR III, a phase 3, double-blind, randomized trial in patients with recurrent clostridioides difficile infection., A Amin, M Sims, C Berenson, E Wang, S Pham, and S Huang
Developing accurate prognostics for sepsis, Alexandra I. Halalau, Francisco R. Davila, Hugo Davila-Grijalva, and Matthew D. Sims
Clinical Pathways Leading to Antibiotic Initiation in Patients with Suspected Infection and Their Association with Delays and Mortality, X Han, C Lopez-Espina, P A. Verhoef, A Spicer, A Bhargava, L Schmalz, Matthew Sims, Alexandra Halalau, Nicholas Maddens, and Aimee Espinosa
Procalcitonin and D-dimer levels at baseline, but not CRP, were informative of COVID-19 hospitalization outcomes, Trini Mathew, Julie George, Christine N. Yost, Mustafa Deebajah, Paul C. Johnson, James Huang, and Christopher F. Carpenter
Investigational Microbiome Therapeutic SER-109 Reduces Recurrence of Clostridioides Difficile Infection (CDI) Compared to Placebo, Regardless of Presence or Absence of Comorbidities Including Chronic Obstructive Disease (COPD) and Asthma, BH McGovern, T Louie, S Cohen, M Sims, E Wang, H Wu, K Brady, and L von Moltke
Combining DRIP Score and Rapid Diagnostics for Improved Antibiotic Stewardship, Richard Ramirez and Matthew Sims
SARS-CoV-2 Immunization/Therapeutics, Matthew Sims
Vaccine Hesitancy Among Healthcare Providers, Matthew Sims
Submissions from 2021
Investigational Microbiome Therapeutic SER-109 Reduces Recurrence of Clostridioides Difficile Infection (CDI) Compared to Placebo, Regardless of Risk Factors for Recurrence, Stuart H. Cohen, Thomas J. Louie, Matthew D. Sims, John Pullman, Elaine E. Wang, and Henry Wu
Cost-Effectiveness Analysis of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Immunocompromised Adults Diagnosed with Select Cancers in the United States, Desmond Curran, Brandon Patterson, Justin Carrico, Ahmed Salem, Elizabeth La, Stephane Lorenc, Katherine Hicks, Sara Poston, and Christopher Carpenter
Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States, Desmond Curran, Ahmed Salem, Stephane Lorenc, Brandon Patterson, Justin Carrico, Katherine A. Hicks, Elizabeth M. La, Sara Poston, and Christopher F. Carpenter
COVID-19 Seropositivity and Asymptomatic Rates in Healthcare Workers at Beaumont, Hans Keil and Matthew D. Sims
Time to Recurrence of Clostridioides Difficile Infection (rCDI) is Rapid Following Completion of Standard of Care Antibiotics: Results from ECOSPOR-III, a Phase 3 Double-Blind, Placebo-Controlled Randomized Trial of SER-109, an Investigational Microbiome Therapeutic, Thomas J. Louic, Matthew D. Sims, Richard Nathan, Steven O'Marro, Princy N. Kumar, Elain E. Wang, and Robert Stevens
Current Challenges in COVID-19 Triaging: A Global Perspective, Mauli Patel, Robin Sudandiradas, Trini Mathew, Paul Kilgore, Mahadev Rao, Chiranjay Mukhopadhay, and Marcus Zervos
Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy With Meropenem, Jason M. Pogue, Michael J. Rybak, Kyle Stamper, Dror Marchaim, Visanu Thamlikitkul, Yehuda Carmeli, and Matthew D. Sims
The Impact of In Vitro Synergy Between Colistin and Meropenem on Clinical Outcomes in Invasive Carbapenem-Resistant Gram-Negative Infections: A Report From the OVERCOME Trial, Jason M. Pogue, Michael J. Rybak, Kyle Stamper, Dror Marchaim, Visanu Thamlikitkul, Yehuda Carmeli, and Matthew D. Sims
Infectious Diseases Research at Beaumont with a Focus on COVID-19, Matthew D. Sims
Kinks and Quirks of Research During A Pandemic., Matthew D. Sims
SARS-CoV-2 Virology and Immunization, Matthew D. Sims
Diagnostic Testing Among Patients With Suspected Recurrent Clostridioides Difficile Infection (rCDI) in ECOSPOR-III a Phase 3 Clinical Trial: Implications for Clinical Practice vs Clinical Trials, Matthew D. Sims, Sahil Khanna, Darrell Pardi, Paul Feuerstadt, Charles Berenson, Henry Wu, and Elaine E. Wang
SER-109, an Investigational Microbiome Therpeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides Difficile Infection (rCDI) After Standard-of-Care Antibiotics, Timothy J. Straub, Liyang Diao, Christopher Ford, Matthew D. Sims, Thomas J. Louie, Charles Berenson, and Colleen S. Kraft
Submissions from 2019
Submissions from 2017
Mycoplasma genitalium Prevalence and Variability Based on Gender, Race and Sexual Preference in Patients Attending the Oakland County Health Department Disease Clinic, Valida Bajrovic and Paul Chittick
Outcome Based Study of Carbapenem Use Relative to ESBLs (OBSCURE), Otavio Pereira Rodrigues and Matthew Sims
Potential Impact of Rapid Diagnostics in Management of Suspected Pneumonia, Matthew Sims